Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis.
The effects of the iron-chelator, desferrioxamine, and monoclonal antibodies against transferrin receptors on DNA synthesis and ribonucleotide reductase activity were examined in human leukemia K562 cells. Treatment of the cells with desferrioxamine resulted in decreases of ribonucleotide reductase activity, DNA synthesis, and cell growth. Exposure of the cells to anti-transferrin receptor antibody, 42/6, which blocks iron supplement into cells caused decreases of ribonucleotide reductase activity and DNA synthesis, in a parallel fashion. Decreases of ribonucleotide reductase activity and DNA synthesis by 42/6 were restored by the addition of ferric nitriloacetate. These results indicate that ribonucleotide reductase activity is dependent on the iron-supply and also regulates cell proliferation.
Furukawa
T
T
Department of Hygiene, Kansai Medical University, Osaka, Japan.
Naitoh
Y
Y
Kohno
H
H
Tokunaga
R
R
Taketani
S
S
D000911:Antibodies, Monoclonal; D002455:Cell Division; D004247:DNA / Q000096:biosynthesis*; D003676:Deferoxamine / Q000494:pharmacology; D005290:Ferric Compounds / Q000494:pharmacology; D006801:Humans; D000090463:Iron Deficiencies; D004915:Leukemia, Erythroblastic, Acute / Q000235:genetics / Q000378:metabolism; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D011990:Receptors, Transferrin / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D005290:Ferric Compounds; D011990:Receptors, Transferrin; D004247:DNA; D012264:Ribonucleotide Reductases; D003676:Deferoxamine; D009571:Nitrilotriacetic Acid; C020326:ferric nitrilotriacetate